PR Newswire Clinical TrialsOriginal article
EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
PartnershipPositive
AI Analysis
Summary
EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate EpiSign's DNA methylation episignature analysis with Geneyx's genomic and multi-omics analysis platform for rare disease applications.
Importance:6/10
Sentiment:
0.60
partnershipcollaborationrare diseasegenomicsepigenomicsDNA methylation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 5, 2026 1:41 PM